Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CISH Biologics Sequence Review Report 2026: Cytokine-inducible SH2-containing protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CISH sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CIB4 Biologics Sequence Review Report 2026: Calcium and integrin-binding family member 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CIB4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CIB3 Biologics Sequence Review Report 2026: Calcium and integrin-binding family member 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CIB3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CIB2 Biologics Sequence Review Report 2026: Calcium and integrin-binding family member 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CIB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CIB1 Biologics Sequence Review Report 2026: Calcium and integrin-binding protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of CIB1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
AR Biologics Sequence Review Report 2026: Androgen receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of AR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
APOBR Biologics Sequence Review Report 2026: Apolipoprotein B receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of APOBR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
APELA Biologics Sequence Review Report 2026: Apelin receptor early endogenous ligand Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of APELA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADGRL3 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor L3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADGRL3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADGRG6 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor G6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADGRG6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADGRG2 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor G2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADGRG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADGRF3 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor F3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ADGRF3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.